ホームページへ

最高の肝動脈化学塞栓療法医師 - トップ28名の医師

コンテンツはBookimed編集ポリシーを満たし、以下により医学的にレビューされています

Fahad Mawlood

Murat Dokdok

  • 肝動脈化学塞栓療法のリーディング医師
  • 4.6 優秀 515 レビュー
  • 26年の経験
  • トルコ, イスタンブール, Anadolu Medical Center
  • Dr. Murat Dokdok is an Interventional Radiologist at the Anadolu Medical Center with expertise in Cardiovasculary Imaging, Neuroradyology, and the ability to communicate in both English and Turkish. He has an extensive educational background, having received a degree from the Istanbul University Cerrahpasha School of Medicine and professional experience from Göztepe State Hospital, Minnesota University and Harvard School of Medicine, MGH, and Acibadem Hospital.
  • 続きを読む
肝動脈化学塞栓療法
$5,000 - $6,000
情報

Eda Tanrikulu

  • 4.6 優秀 515 レビュー
  • 21年の経験
  • トルコ, イスタンブール, Anadolu Medical Center
  • エダ・タンルクル医師はアナドル医療センターにて腫瘍内科および化学療法を専門とし、肝臓がん治療に重点を置いています。

    • マルマラ大学にて腫瘍内科の研修を修了
    • トルコの専門医資格試験にて全国3位を獲得
    • ハイダルパシャ・ヌムネ研修研究病院にて腫瘍内科部門を統括
    • 国際臨床試験に参加
  • 続きを読む
肝動脈化学塞栓療法
$5,000 - $6,000
情報

Mustafa Solak

  • 肝動脈化学塞栓療法のリーディング医師
  • 4.6 優秀 216 レビュー
  • 20年の経験
  • トルコ, イスタンブール, Hisar Hospital Intercontinental
  • Solak医師はHisar Hospital Intercontinentalにて化学塞栓療法を専門とし、Hacettepe大学がん研究所にて研修を受けました。

    • Hacettepe大学がん研究所にてフェローシップを修了
    • テキサス大学MDアンダーソンがんセンターに勤務
    • 消化器がんをはじめとする各種腫瘍を専門とする
    • 専門医資格を取得し、腫瘍学における豊富な研修経験を有する
  • 続きを読む
診察
お問い合わせください
情報

Pelles Sharon

  • 4.5 良い 156 レビュー
  • 23年の経験
  • イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
  • ペレス・シャロン医師は、スラスキー医療センター(イチロフ)において、化学塞栓療法をはじめとする進行肝癌の高度治療を専門としています。

    • 肝臓手術を中心に、多様な癌治療における豊富な経験を有する
    • 腫瘍患者の治療に対する意識に関する臨床研究に貢献
    • 外科的および非外科的肝癌療法の双方に精通
    • 各患者に対して個別化された治療計画を提供
  • 続きを読む
診察
お問い合わせください
情報

Ofer Merimsky

  • 4.5 良い 156 レビュー
  • 41年の経験
  • 認定:
  • イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
  • オフェル・メリムスキー教授は、骨腫瘍・軟部腫瘍・中皮腫・肺癌・肝臓および肺への転移性病変を専門とする著名な腫瘍内科医です。スラスキー医療センター(イヒロフ、テルアビブ)の骨格・軟部腫瘍科の科長を務め、イスラエル臨床腫瘍医協会の会長を兼任しています。

    主な専門領域と患者様へのメリット:

    • 豊富な臨床経験と国際的な診療実績として、米国・フランス・イスラエルでの研修歴およびエルサレム大学での教育活動が挙げられ、高精度の先進的診断・治療法の提供が可能です。
    • 腫瘍科的治療法には、肉腫・中皮腫・骨格および軟部腫瘍の治療のほか、放射線療法および小線源治療が含まれます。希少かつ難治性の腫瘍疾患に対しても、患者様は包括的な治療を受けることができます。
    • 権威ある学術誌への多数の論文掲載実績として、New England Journal of Medicine(N Engl J MedAnnals of Oncology、および欧州臨床腫瘍学会(European Society for Medical Oncology、ESMO)関連誌への発表があり、患者様が最新かつエビデンスに基づいた治療法を受けられることを保証しています。
    • 国際学術団体への加盟として、Society of Oncologists and Radiotherapists Israel、ASCO、EMSOS、CTOSへの所属が、その高い専門性を証明するとともに、最新の治療プロトコルへのアクセスを可能にしています。
    • オンライン診療を通じた遠隔診察・助言の提供が可能であり、世界どこからでも専門家による医療支援を受けることができます。

    患者様はメリムスキー教授の深い腫瘍学的知識、個別化された治療計画の立案能力、そして細やかな対応を高く評価しており、治療の全過程を通じて安心感と信頼感が得られると好評です。

  • 続きを読む
診察
お問い合わせください
情報

Yesim Yildirim

  • 4.6 優秀 515 レビュー
  • 22年の経験
  • 認定:
  • トルコ, イスタンブール, Anadolu Medical Center
  • イェシム(Yeşim)・ユルドゥルム教授は、Anadolu Medical Centerの腫瘍内科専門医です(2011年より在籍)。ESMO認定専門医であり、2021年より教授職を務め、80本以上の学術論文を執筆しています。Rambam(イスラエル)およびMount Vernon(英国)の主要医療機関で研修を修了。乳癌、肺癌、消化管癌、悪性黒色腫、肉腫の治療を専門とし、免疫療法および分子標的療法を実施しています。

    患者がイェシム・ユルドゥルム医師を選ぶ理由:

    • 20年以上の臨床経験を有し、2021年より腫瘍内科学の教授を務めています。
    • 腫瘍生物学・免疫療法・分子標的療法に関する査読済み論文を80本以上執筆しており、治療計画は最新のエビデンスに基づいています。
    • 欧州を代表する腫瘍学会であるESMOの認定資格を取得しており、高度な専門性と国際基準に沿った継続的な研鑽を証明しています。
  • 続きを読む
肝動脈化学塞栓療法
$5,000 - $6,000
情報

Ido Wolf

  • 4.5 良い 156 レビュー
  • 34年の経験
  • 認定:
  • イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
  • ソウラスキー医療センター腫瘍内科部長であるウルフ博士は、腫瘍学および内科における豊富な専門知識を有しています。

    • 肝臓の化学塞栓療法を専門とする
    • ベン=グリオン大学(ネゲブ)卒業
    • 軍医療部隊での経験あり
診察
お問い合わせください
情報

Ari Raphael

  • 4.5 良い 156 レビュー
  • 29年の経験
  • 認定:
  • イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
  • アリ・ラファエル教授――テルアビブ・スラスキー医療センター(イキロフ、テルアビブ)トランスレーショナル腫瘍学部門長および臨床がん研究部門研究員。患者一人ひとりのニーズに寄り添う個別対応のアプローチが高く評価されています。

    資格および患者への貢献:

    • 腫瘍科デイホスピタルを統括し、国家ゲノム医療プロジェクトを主導。最先端の研究へのアクセスを提供しています。

    • 主任副研究者および主任研究者として、腫瘍内mRNA投与やウイルス製剤を含むフェーズI〜IIIの多数の臨床試験に携わってきました。患者は革新的な治療法への参加機会を得られます。

    • 米国および英国における国際的な臨床経験を有し、世界水準の治療基準と先進的なプロトコルの適用を保証しています。

    • 国際学術団体の会員ESMOIASLCISLB、ISCORT、Israeli Medical Association)。最新の治療基準を活用し、国際的な研究に参画しています。

    •  ICH GCP R2、Israeli MOH Guidelinesをはじめ、インフォームドコンセント、副作用管理および患者安全に関する最新課程を含む国際臨床実践基準に基づき、定期的に専門知識の更新および研修を実施しています。

    ラファエル教授は、精密な治療レジメンの選択、革新的手法の導入、そして細やかな患者対応により高い信頼を得ており、治療のすべての段階において患者が安心して療養に臨める環境を提供しています。

  • 続きを読む
診察
お問い合わせください
情報

Mustafa Serkan Alemdar

  • 4.5 良い 6 レビュー
  • 20年の経験
  • トルコ, アンタルヤ, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • 続きを読む
診察
お問い合わせください
情報

Irina Stepfansky

  • 4.5 良い 156 レビュー
  • 26年の経験
  • イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
  • Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

    Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

  • 続きを読む
診察
お問い合わせください
情報

Menahem Ben-haim

  • 4.5 良い 156 レビュー
  • 32年の経験
  • イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
  • Included in the list of the best doctors in Israel 2021 by the international edition of Forbes. Awards and prizes: 2001 - R. Vishnitzer Prize for the best presentation, 22nd Conference of the Israeli Society of Surgery. 2001 - Best poster, 8th annual conference of the Israel Transplant Association. 2007 - R. Vishnitzer Prize for the best oral presentation, 25th Conference of the Association of Israeli Surgeons.
  • 続きを読む
診察
お問い合わせください
情報

Tahsin Ozatli

  • 4.3 良い 18 レビュー
  • 2016年の経験
  • トルコ, イスタンブール, Istinye University Liv Hospital Bahcesehir
  • Oncologist
診察
お問い合わせください
情報

Sebastian Keil

  • 4.7 優秀 61 レビュー
  • 22年の経験
  • ドイツ, ゾーリンゲン, Medical Center in Solingen
  • Professor Dr. Sebastian Keil is a recognized expert in the field of interventional radiology and is considered one of the leading specialists in Germany and in Europe. He is a professional in his field, thanks to whom many patients receive timely diagnosis and effective treatment. Professor Keil and his team of specialists have extensive knowledge of anatomy, physiology and pathology, as well as an understanding of the various methods of performing and interpreting radiological examinations.
  • 続きを読む
診察
お問い合わせください
情報

Irfan Cicin

  • 5 優秀 1 レビュー
  • 29年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • 続きを読む
診察
お問い合わせください
情報

Ercan Ozden

  • 5 優秀 1 レビュー
  • 27年の経験
  • トルコ, イスタンブール, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • 続きを読む
診察
お問い合わせください
情報

Nail Paksoy

  • 4.5 良い 2 レビュー
  • 15年の経験
  • 認定:
  • トルコ, イスタンブール, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • 続きを読む
診察
お問い合わせください
情報

Muhammed Mustafa Atci

  • 5 優秀 1 レビュー
  • 15年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • 続きを読む
診察
お問い合わせください
情報

Ercan Kocakoc

  • 新着
  • 33年の経験
  • トルコ, イスタンブール, Medical Park Bahcelievler Hospital
  • Academic Details

    Faculty / University
    19 Mayis University, Faculty of Medicine, Samsun – Turkey

    Date of Graduation
    1992

    Postgraduate Training
    Institution: Department of Radiology, Faculty of Medicine, Erciyes University, Kayseri – Turkey
    Supervisor in Charge of Training: Mustafa Ozturk
    Training Period: From 1993 to 1998
    Title of Thesis: Evaluation of Lower Extremity Artery-Occlusive Disease by MR Angiography

    Accreditation

    Radiology Specialist: 1998, The Ministry of Health of Turkey

    Associate Professor: 2003, Interuniversity Committee

    Academic Experience

    Residency: Department of Radiology, Erciyes University, Kayseri – Turkey (1993 to 1998)

    Private Practice: Maternal and Children Hospital, Sivas – Turkey (1998–2000)

    Academic Positions:

    2000 to 2003: Assistant Professor of Radiology, Firat University, Elazig – Turkey

    2003 to 2009: Associate Professor of Radiology, Firat University, Elazig – Turkey

    2009 to 2010: Professor of Radiology, Firat University, Elazig – Turkey

    2010 to 2015: Professor of Radiology, Chairman, Bezmialem Vakif University, Istanbul – Turkey

    2015 to 2016: Professor of Radiology, Chairman, Yeditepe University, Istanbul – Turkey

    2017 to Present: Professor of Radiology, Interventional Radiology Unit, Bahçelievler Medical Park Hospital, Altınbaş University, Istanbul – Turkey

    Fellowship

    Institution: Department of Radiology, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA

    Duration:  2004 to 2005

    Position: Research Fellow – Ultrasound & CT (Body)

    Professional Memberships

    -Turkish Society of Radiology

    -Medical Ultrasound Society of Turkey

    -Turkish Society of Radiology, Abdominal Radiology Study Group

    -ESGAR – European Society of Gastrointestinal and Abdominal Radiology (Fellow)

    -ESUR – European Society of Urogenital Radiology (Fellow)

    -ESR – European Society of Radiology

    -Turkish Society of Magnetic Resonance

    -Turkish Society of Radiology, Urogenital Radiology Study Group

    -Turkish Society of Interventional Radiology

    -Korean Society of Radiology (International Member)

    -Radiological Society of North America (RSNA) – Corresponding Member

    Prizes and Awards

    European Congress of Radiology (ECR) 2002, Vienna – Image Interpretation, 3rd Prize

    Interpretation Corner of European Radiology 20032nd Prize

    Cases of the Day – ESGAR 2007, Lisbon, Portugal – 2nd Prize

    Cases of the Day – ESGAR 2009, Valencia, Spain – 1st Prize

  • 続きを読む
診察
お問い合わせください
情報

Muhammed Gomec

  • 5 優秀 1 レビュー
  • 17年の経験
  • トルコ, スィヴァス, Medicana Sivas Hospital
診察
お問い合わせください
情報

適切な医師とクリニックの選び方:内部者のヒント

医師やクリニックを選ぶ際は、これらの重要なポイントを覚えておいてください:
資格を確認
ISAPS、JCI、または関連医学会などの機関からの認証を確認してください
成功率を確認
お客様の特定治療に豊富な経験と実績のある医師をお選びください
患者レビューを読む
実際の患者様のBookimedレビューをご覧になり、体験について学んでください
効果的なコミュニケーションの確保
円滑な治療のため言語サポートを提供するクリニックを選んでください。
サービスについて質問
隠れた費用を避けるため、価格に宿泊、現地送迎、アフターケアなどのサービスが含まれているかご確認ください
海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。
ヤン・マツィイフスキー
医療コーディネーターチーム責任者

Bookimed洞察:世界のトップ肝動脈化学塞栓療法専門家(2026)

Bookimedは肝動脈化学塞栓療法のグローバルリクエスト100件を調整し、28名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年グローバルランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています
順位医師経験適合する方特色クリニックと所在地診察
#121年の経験肝癌の治療法肝臓癌を専門とする腫瘍内科医。トルコの専門医試験で3位を獲得し、臨床研究を主導している。
トルコ
から $215
#220年の経験肝化学塞栓療法一流のがん専門機関での研修を経て、化学塞栓療法を専門とする。MDアンダーソンがんセンターでの勤務経験を持ち、高度な技術を導入している。
トルコ
から $100
#323年の経験肝化学塞栓術化学塞栓術や高周波焼灼術を含む進行肝癌治療を専門とし、腫瘍患者ケアに関する臨床研究に貢献している。
イスラエル
から $825
#434年の経験肝化学塞栓術ソウラスキー医療センターの腫瘍内科部門を統括。化学塞栓療法を専門とし、腫瘍学における豊富な経験を有する。
イスラエル
お問い合わせください